Diego A. Díaz García, Medical Oncologist / CEO / Founder at CánCare – Advanced Specialty in Oncology, shared a post on X:
“Survival of patients with Lung Adenocarcinoma diagnosed in 2000, 2010, and 2020.
Median OS in lung adenocarcinoma more than doubled in 20 years (8.5 → 20.7 months) in non-academic public hospitals in France.
Targeted therapy and immunotherapy significantly improved outcomes, even outside academic centers.”
Title: Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020
Journal: NEJM Evidence
Authors: Didier Debieuvre, Lionel Falchero, Olivier Molinier, Sébastien Couraud, Alexis Cortot, Nicolas Meyer, Bernard Asselain, Etienne Auvray, Dorine Templement-Grangerat, Acya Bizieux, Jean Tredaniel, Sophie Schneider, Jean-Bernard Auliac, Olivier Bylicki, Alexia Letierce, Hugues Morel
More posts featuring Diego A. Díaz García on OncoDaily.
